ChemicalBook--->CAS DataBase List--->1448723-60-1

1448723-60-1

1448723-60-1 Structure

1448723-60-1 Structure
IdentificationBack Directory
[Name]

UM729
[CAS]

1448723-60-1
[Synonyms]

C07
UM729
CS-1240
UM-729;UM 729
UM729 USP/EP/BP
methyl 4-(3-(piperidin-1-yl)propylamino)-9H-pyrimido[4,5-b]indole-7-carboxylate
4-[[3-(1-Piperidinyl)propyl]amino]-9H-pyrimido[4,5-b]indole-7-carboxylic acid methyl ester
9H-Pyrimido[4,5-b]indole-7-carboxylic acid, 4-[[3-(1-piperidinyl)propyl]amino]-, methyl ester
[Molecular Formula]

C20H25N5O2
[MDL Number]

MFCD28167784
[MOL File]

1448723-60-1.mol
[Molecular Weight]

367.44
Safety DataBack Directory
[Symbol(GHS) ]


GHS07
[Signal word ]

Warning
[Hazard statements ]

H302-H315-H319-H335
[Precautionary statements ]

P261-P305+P351+P338
Hazard InformationBack Directory
[Biological Activity]

UM729 is an enhancer of aryl hydrocarbon receptor (AhR) antagonists.
[in vitro]

um729 expands normal hematopoietic stem and progenitor cells (HSPC) in an AhR-independent manner, and UM729 inhibits AML cell differentiation. In 05H163 cells, the addition of UM729 increased CD34+CD15- Number of cells. It can inhibit the differentiation of most AML cells in combination with AhR antagonists.
[in vivo]

In NSG mice, UM729, alone or in combination with SR1, enhanced engraftment but not leukemia stem cell (LSC) frequency distribution.
Tags:1448723-60-1 Related Product Information
1227633-49-9

  • HomePage | Member Companies | Advertising | Contact us | Previous WebSite | MSDS | CAS Index | CAS DataBase | Privacy | Terms | About Us
  • All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
    According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.
  • Copyright © 2023 ChemicalBook All rights reserved.